scorecardresearch
Add as a preferred source on Google
Friday, October 3, 2025
Support Our Journalism
HomeEconomyNatco Pharma files generic Olaparib tablets in US

Natco Pharma files generic Olaparib tablets in US

Follow Us :
Text Size:

New Delhi [India], February 13 (ANI): Natco Pharma on Monday said it has submitted Abbreviated New Drug Application (ANDA) certification with the US Food and Drug Administration (FDA) for the generic version of Olaparib Tablets — of 100mg and 150mg.

Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer. It is marketed in the US by AstraZeneca under brand Lynparza.

“NATCO and its co-development and marketing partner Alembic Pharmaceuticals believe that the ANDA is possibly sole first-to-file based on its filing date and may be eligible for 180 days of marketing exclusivity at the time of launch of the product,” the pharma company said in a regulatory filing to the exchanges.

In 2022, Lynparza has recorded sales of USD 1,226 million in the US market, the filing said, citing AstraZeneca results presentation. (ANI)

This report is auto-generated from ANI news service. ThePrint holds no responsibility for its content.

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

  • Tags

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular